DGAP-News

CEVEC's CAP(R)Go derived recombinant placental human alkaline phosphatase shows superior results in a preclinical study

DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Study/Study
results
CEVEC's CAP(R)Go derived recombinant placental human alkaline
phosphatase shows superior results in a preclinical study

06.07.2015 / 08:30

---------------------------------------------------------------------

CEVEC's CAP(R)Go derived recombinant placental human alkaline phosphatase
shows superior results in a preclinical study

- New CAP(R)Go cell line for the production of glyco-optimized
recombinant human alkaline phosphatase successfully established

- CAP(R)Go derived recombinant human alkaline phosphatase optimized to
address therapeutic needs in chronic inflammatory indications and
neurodegenerative diseases

Cologne, Germany, July 06, 2015 - CEVEC Pharmaceuticals GmbH (CEVEC), the
expert in the production of tailor-made recombinant glycoproteins, today
announced the results of a preclinical animal study in which its CAP(R)Go
derived recombinant placental human alkaline phosphatase (PLAP) showed
significantly prolonged serum-half-life.

The Company's glyco-optimized PLAP displayed a four times longer serum
half-life in a pivotal rat study in comparison to an earlier recombinant
version of the molecule. The new PLAP molecule originates from a newly
developed cell line of CEVEC's recently introduced CAP(R)GO technology,
which provides for specifically improved glycosylation patterns.

Today, various alkaline phosphatase (AP) isoforms are under development for
the treatment of acute and chronic inflammatory diseases such as Rheumatoid
arthritis. Additionally, chronic degenerative diseases such as Alzheimer's
disease or Amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) are
being considered promising therapeutic indications for alkaline
phosphatases. Currently, ongoing clinical trials are being conducted with
purified proteins from either bovine intestinal tissues or with
non-naturally occurring reassembled recombinant versions of these
molecules. The molecule developed by CEVEC, a recombinant wild-type version
of a fully-human AP with a high, specific activity and a prolonged
serum-half life, is expected to become the preferred alternative for these
approaches.

The observed superior pharmacokinetic properties of CAP(R)Go derived PLAP
hold promise to affect the therapeutic efficacy of the molecule. This may